RT Journal
A1 Hampton T
T1 SAfer cancer drug
JF JAMA
JO JAMA
YR 2013
FD February 6
VO 309
IS 5
SP 431
OP 431
DO 10.1001/jama.2013.269
UL http://dx.doi.org/10.1001/jama.2013.269
AB 
In cancer cells, navitoclax targets BCL-2, a prosurvival protein (a molecule that helps the cancer cell evade programmed cell death). But navitoclax also inhibits BCL-2–like 1 (BCL-XL), which is a related factor required for the survival of platelets. Therefore, treatment with the drug often causes thrombocytopenia.